These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 24766376)

  • 1. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
    Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
    Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are C-reactive protein and ferritin levels being overlooked in indigenous australians with chronic kidney disease?
    Claes J; Ellis JA; Rettie F; Butcher B; Bradley J
    J Ren Care; 2013 Sep; 39(3):176-81. PubMed ID: 23763720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
    Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
    Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study.
    Panichi V; Rosati A; Bigazzi R; Paoletti S; Mantuano E; Beati S; Marchetti V; Bernabini G; Grazi G; Rizza GM; Migliori M; Giusti R; Lippi A; Casani A; Barsotti G; Tetta C;
    Nephrol Dial Transplant; 2011 Aug; 26(8):2641-8. PubMed ID: 21325348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients.
    Petrulienė K; Žiginskienė E; Kuzminskis V; Nedzelskienė I; Bumblytė IA
    Medicina (Kaunas); 2017; 53(2):90-100. PubMed ID: 28416170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency.
    Won HS; Kim HG; Yun YS; Jeon EK; Ko YH; Kim YS; Kim YO; Yoon SA
    Hemodial Int; 2012 Jan; 16(1):31-7. PubMed ID: 22284696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage.
    Kuragano T; Kitamura K; Matsumura O; Matsuda A; Hara T; Kiyomoto H; Murata T; Fujimoto S; Hase H; Joki N; Fukatsu A; Inoue T; Itakura Y; Nakanishi T
    PLoS One; 2016; 11(3):e0147328. PubMed ID: 26933949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
    Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
    Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
    Vaziri ND; Kalantar-Zadeh K; Wish JB
    Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
    Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
    BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
    Malovrh M; Hojs N; Premru V
    Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
    Rao A; Gilg J; Williams A
    Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.